Concord Biotech Limited reported a 30% decline in consolidated net profit for the financial year ended March 31, 2026, to ₹259.2 crore, down from ₹371.6 crore in the previous year. Consolidated revenue from operations fell 12% to ₹1,054.9 crore from ₹1,200.1 crore in FY25. The company attributed the performance to delays in customer procurement decisions, uncertainty related to US tariff measures, and geopolitical disruptions. For the quarter ended March 31, 2026, consolidated net profit stood at ₹88.5 crore on revenue of ₹326.1 crore.

Financial Performance

The consolidated EBITDA for FY26 stood at ₹367.4 crore, a decline of 27% from ₹506.3 crore in the previous year, with an EBITDA margin of 34.8%. The company reported an exceptional item of ₹3.3 crore related to the statutory impact of new labour codes. The following table presents the key consolidated financial metrics for the quarter and full year ended March 31, 2026:

Segment and Geography Performance

Revenue from the API segment stood at ₹828.8 crore for FY26, while the formulation segment contributed ₹226.1 crore. Geographically, domestic revenue was ₹563.6 crore, and exports revenue was ₹491.3 crore for the full year. The company noted that EBITDA margins, excluding the impact of the formulation facility and expenses related to newly incorporated subsidiary Stellon Biotech, stood at 40.4% for Q4FY26 and 38.8% for FY26.

Dividend Declaration

The Board of Directors recommended a final dividend of ₹7.55 per equity share of face value Re. 1 each for the financial year 2025-26. This dividend is subject to the approval of shareholders at the ensuing Annual General Meeting. The board fixed July 24, 2026, as the record date for identifying eligible shareholders.

Management Commentary

Ankur Vaid, Joint Managing Director & Chief Executive Officer, stated that FY26 was challenging due to customers shifting from bulk purchasing to staggered procurement. He highlighted that the company completed multiple global regulatory inspections, including USFDA and EU-GMP, and progressed the commercialization of injectable and soft gel facilities. Vaid expressed optimism for FY27, citing a strong customer acquisition pipeline and order enquiries.

Concord Biotech faces a challenging outlook as Citi maintains its Neutral rating while implementing significant downgrades to financial projections and target price. The brokerage has cut the target price substantially from ₹1,680 to ₹1,190, reflecting concerns about the company's near-term performance across multiple business segments.

Substantial EPS Downgrades

Citi has implemented significant earnings downgrades for Concord Biotech, cutting EPS estimates by 20-23% for FY26-27. This substantial revision reflects the brokerage's concerns about the company's ability to maintain its historical growth trajectory amid current market challenges.

Multiple Business Headwinds

The pharmaceutical company is facing challenges across several fronts that have prompted the analyst downgrades. The slowdown in API (Active Pharmaceutical Ingredients) and formulations business represents a core concern, as these segments form the backbone of Concord Biotech's operations. Additionally, margin compression is expected to impact profitability metrics going forward.

Regulatory and Market Challenges

Several temporary but significant headwinds are affecting the company's operational performance:

• Tariff-related pressures impacting cost structures
• Middle East tender delays affecting revenue recognition timelines
• CDSCO approval delays creating regulatory bottlenecks
• Increased competitive pressures in key market segments

Revised Growth Projections

Citi has also adjusted its longer-term growth expectations for Concord Biotech, reducing the projected revenue growth for FY27-28 to approximately 14%. This represents a more conservative outlook compared to previous estimates, reflecting the sustained impact of current market conditions on the company's growth trajectory.

Valuation Methodology Adjustment

As part of the comprehensive review, Citi has also modified its valuation approach by cutting the target multiple to 20x EBITDA. This adjustment in the valuation framework, combined with the reduced earnings projections, has contributed to the significant reduction in the target price from ₹1,680 to ₹1,190.